摘要
系统评价参松养心胶囊治疗缓慢性心律失常合并早搏的疗效和安全性的Meta分析。计算机检索中国知网数据库(CNKI)、万方数据资源系统、维普中文科技期刊全文数据库(VIP)、中国生物医学文献服务系统(SinoMed)、PubMed和Cochrane图书馆、ClinicalTrials数据库,收集参松养心胶囊治疗缓慢性心律失常合并早搏的随机对照试验。由2名研究者独立根据纳排标准筛选文献、资料提取并核对结果,采用Risk of Bias工具进行方法学质量评估,采用RevMan 5.3进行Meta分析。共纳入9篇随机对照试验,包含受试者706名,干预措施为单独使用参松养心胶囊,对照措施为空白对照。结果显示,参松养心胶囊对平均心率(MD=6.59,95%CI[3.87,9.31],I^2=90%)、早搏有效率(RR=1.72,95%CI[1.53,1.93],I^2=0%)、心动过缓有效率(RR=1.74,95%CI[1.40,2.17],I^2=47%)、临床有效率(RR=1.50,95%CI[1.31,1.70],I^2=31%)均有一定疗效。8项研究报告安全性事件,未发现明显不良反应。该研究发现,单独使用参松养心胶囊对缓慢性心律失常合并早搏在提高心率,控制早搏及改善临床症状方面可能具有一定疗效,未发现明显不良反应,临床可考虑使用。该结论仍需开展高质量的临床试验进一步加以证实。
To analyze the efficacy and safety of Shensong Yangxin Capsules in treatment of bradycardia combined with premature beat.Databases,such as CNKI,VIP,WanFang,SinoMed,PubMed,Cochrane Library,ClinicalTrials were retrieved by computers for relevant randomized controlled trials of Shensong Yangxin Capsules in treatment of bradycardia combined with premature beat.Two researchers independently screened out the literatures,extracted data according to the inclusion criteria,and applied the Risk of Bias assessment tool in assessing the methodological quality.The Cochrane systematic evaluation software RevMan 5.3 was used for data analysis.Totally 9 randomized controlled trials including 706 subjects were included.The intervention measure was the single administration with Shensong Yangxin Capsules,and the control measure was the blank control.The results showed that Shensong Yangxin Capsules had an obvious effect on average heart rate(MD=6.59,95%CI[3.87,9.31],I^2=90%),premature beat efficacy(RR=1.72,95%CI[1.53,1.93],I^2=0%),heart rate efficacy(RR=1.74,95%CI[1.40,2.17],I^2=47%),and objective efficacy(RR=1.50,95%CI[1.31,1.70],I^2=31%).Eight studies reported safety events,with no significant adverse reaction.In conclusion,the single administration with Shensong Yangxin Capsules may have a certain effect in improving heart rate,controlling premature beats and alleviating clinical symptoms in patients with bradycardia combined with premature beat,with no obvious adverse reaction.Shensong Yangxin Capsules can be used in clinic.This potential conclusion needs to be confirmed in future trials using rigorous methodology.
作者
杨昊昕
戴雁彦
宫僖浩
赵国桢
苟金
张秀文
辛玉
李博
YANG Hao-xin;DAI Yan-yan;GONG Xi-hao;ZHAO Guo-zhen;GOU Jin;ZHANG Xiu-wen;XIN Yu;LI Bo(Dongzhimen Hospital,Beijing University of Chinese Medicine,Beijing 100700,China;Beijing Hospital of Traditional Chinese Medicine,Capital Medical University,Beijing 100010,China;Beijing Institute of Traditional Chinese Medicine,Beijing 100010,China;Dongfang Hospital,Beijing University of Chinese Medicine,Beijing 100078,China)
出处
《中国中药杂志》
CAS
CSCD
北大核心
2020年第2期436-443,共8页
China Journal of Chinese Materia Medica
基金
国家自然科学基金项目(81774146).
作者简介
杨昊昕,硕士研究生,E-mail:yhx122401@163.com;通信作者:李博,副主任医师,研究方向为中西医临床疗效评价及循证医学,E-mail:dr.libo@vip.163.com
